Literature DB >> 31685109

ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer.

Brian C Allen1, Aytekin Oto2, Oguz Akin3, Lauren F Alexander4, Jaron Chong5, Adam T Froemming6, Pat F Fulgham7, Shane Lloyd8, Jodi K Maranchie9, Rekha N Mody10, Bhavik N Patel11, Nicola Schieda12, Ismail B Turkbey13, Neha Vapiwala14, Aradhana M Venkatesan15, Carolyn L Wang16, Don C Yoo17, Mark E Lockhart18.   

Abstract

Urothelial cancer is the second most common cancer, and cause of cancer death, related to the genitourinary tract. The goals of surveillance imaging after the treatment of urothelial cancer of the urinary bladder are to detect new or previously undetected urothelial tumors, to identify metastatic disease, and to evaluate for complications of therapy. For surveillance, patients can be stratified into one of three groups: (1) nonmuscle invasive bladder cancer with no symptoms or additional risk factors; (2) nonmuscle invasive bladder cancer with symptoms or additional risk factors; and (3) muscle invasive bladder cancer. This article is a review of the current literature for urothelial cancer and resulting recommendations for surveillance imaging. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
Copyright © 2019 American College of Radiology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AUC; Appropriate Use Criteria; Appropriateness Criteria; Bladder cancer; Muscle invasive bladder cancer; Nonmuscle invasive bladder cancer; Surveillance; Transitional cell carcinoma; Urothelial cancer

Mesh:

Year:  2019        PMID: 31685109     DOI: 10.1016/j.jacr.2019.05.026

Source DB:  PubMed          Journal:  J Am Coll Radiol        ISSN: 1546-1440            Impact factor:   5.532


  4 in total

Review 1.  The Role of Imaging in Bladder Cancer Diagnosis and Staging.

Authors:  Samuel J Galgano; Kristin K Porter; Constantine Burgan; Soroush Rais-Bahrami
Journal:  Diagnostics (Basel)       Date:  2020-09-16

Review 2.  Contrast-Associated Acute Kidney Injury: Advances and Challenges.

Authors:  Qingqing Li; Shengqi Pan
Journal:  Int J Gen Med       Date:  2022-02-15

Review 3.  Approaches to Non-Muscle-Invasive Bladder Cancer.

Authors:  Hannah Slovacek; Jerry Zhuo; Jennifer M Taylor
Journal:  Curr Oncol Rep       Date:  2021-07-16       Impact factor: 5.075

Review 4.  Imaging and Management of Bladder Cancer.

Authors:  Vincenzo K Wong; Dhakshinamoorthy Ganeshan; Corey T Jensen; Catherine E Devine
Journal:  Cancers (Basel)       Date:  2021-03-19       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.